Cargando…
Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus
To identify the clinical and pharmacological risk factors associated with tacrolimus pharmacodynamics for acute graft‐versus‐host disease (aGVHD) in pediatric patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) from a matched related donor. A retrospective cohort single cent...
Autores principales: | Phan, Michael, Chavan, Rishikesh, Beuttler, Richard, Benipayo, Nicole, Magedman, Grace, Buchbinder, David, Tomaszewski, Daniel, Yang, Sun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301588/ https://www.ncbi.nlm.nih.gov/pubmed/33503293 http://dx.doi.org/10.1111/cts.12982 |
Ejemplares similares
-
Elevation of tacrolimus concentration after administration of methotrexate for treatment of graft-versus-host disease in pediatric patients received allogeneic hematopoietic stem cell transplantation
por: Inoue, Chiaki, et al.
Publicado: (2023) -
Visilizumab with Tacrolimus and Methotrexate for Graft-Versus-Host Disease Prevention After Allogeneic Hematopoietic Cell Transplantation From Mismatched Unrelated Donors
por: Perez, Lia Elena, et al.
Publicado: (2016) -
Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
por: Vondrak, Karel, et al.
Publicado: (2019) -
Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
por: Sharma, Nidhi, et al.
Publicado: (2021) -
Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation
por: Uppugunduri, C. R. S., et al.
Publicado: (2021)